Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

被引：0
|
作者：
Laila König
Klaus Herfarth
Juliane Hörner-Rieber
Sascha Dietrich
Thomas Wiegel
Jürgen Debus
Andreas Viardot
机构：
[1] University Hospital Heidelberg,Department of Radiation Oncology
[2] Heidelberg Institute of Radiation Oncology (HIRO),Department of Internal Medicine V
[3] National Center for Tumor diseases (NCT),Department of Radiation Oncology
[4] University Hospital Heidelberg,Department of Internal Medicine III
[5] University Hospital Ulm,undefined
[6] University Hospital Ulm,undefined
来源：
Strahlentherapie und Onkologie | 2020年 / 196卷
关键词：
Radioimmunotherapy; Immunotherapy; Indolent lymphoma; CD20 antibody; Grade 3A follicular lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：705 / 714
页数：9
相关论文
共 50 条
  • [31] Therapy of the follicular non-Hodgkin's lymphoma (WHO Grade 1/2) in the clinical stage 1/2using involved-field radiation combined with Rituximab - MIR Study
    Herfarth, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 47 - 47
  • [32] Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation
    Guckenberger, Matthias
    Alexandrow, Nikolaus
    Flentje, Michael
    RADIATION ONCOLOGY, 2012, 7
  • [33] Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation
    Matthias Guckenberger
    Nikolaus Alexandrow
    Michael Flentje
    Radiation Oncology, 7
  • [34] First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma
    Wang, Liang
    Wang, Zhi-hui
    Chen, Xiao-qin
    Li, Ya-jun
    Wang, Ke-feng
    Xia, Yun-fei
    Xia, Zhong-jun
    CANCER, 2013, 119 (02) : 348 - 355
  • [35] MILD TOXICITY AND FAVORABLE PROGNOSIS OF HIGH-DOSE AND EXTENDED INVOLVED-FIELD INTENSITY-MODULATED RADIOTHERAPY FOR PATIENTS WITH EARLY-STAGE NASAL NK/T-CELL LYMPHOMA
    Wang, Hua
    Li, Ye-Xiong
    Wang, Wei-Hu
    Jin, Jing
    Dai, Jian-Rong
    Wang, Shu-Lian
    Liu, Yue-Ping
    Song, Yong-Wen
    Wang, Zhao-Yang
    Liu, Qing-Feng
    Fang, Hui
    Qi, Shu-Nan
    Liu, Xin-Fan
    Yu, Zi-Hao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (03): : 1115 - 1121
  • [36] MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results
    Zinzani, PL
    Stefoni, V
    Tani, M
    Barbieri, E
    Albertini, P
    Vigna, E
    Gherlinzoni, F
    Alinari, L
    Galuppi, A
    Pileri, S
    Babini, L
    Tura, S
    LEUKEMIA & LYMPHOMA, 2001, 42 (05) : 989 - 995
  • [37] Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy
    Senan, S
    Burgers, S
    Samson, MJ
    Van Klaveren, RJ
    Oei, SS
    De Koste, JV
    Voet, PWJ
    Lagerwaard, FJ
    Van Haarst, JM
    Aerts, JGJV
    Van Meerbeeck, JP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04): : 999 - 1006
  • [38] Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome
    Nielsen, Karin
    Maraldo, Maja Vestmoe
    Berthelsen, Anne Kiil
    Loft, Annika
    Brown, Peter de Nully
    Vogelius, Ivan Richter
    Petersen, Peter Meidahl
    Specht, Lena
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : 230 - 238
  • [39] PREDICTED RISK OF RADIATION-INDUCED CANCERS AFTER INVOLVED FIELD AND INVOLVED NODE RADIOTHERAPY WITH OR WITHOUT INTENSITY MODULATION FOR EARLY-STAGE HODGKIN LYMPHOMA IN FEMALE PATIENTS
    Weber, Damien C.
    Johanson, Safora
    Peguret, Nicolas
    Cozzi, Luca
    Olsen, Dag R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : 490 - 497
  • [40] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
    Engert, A
    Schiller, P
    Josting, A
    Herrmann, R
    Koch, P
    Sieber, M
    Boissevain, F
    de Wit, M
    Mezger, J
    Dühmke, E
    Willich, N
    Müller, RP
    Schmidt, BF
    Renner, H
    Müller-Hermelink, HK
    Pfistner, B
    Wolf, J
    Hasenclever, D
    Löffler, M
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
12345